Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX) (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it has appointed Dr. Aaron Schwartz, a veteran of Teva Pharmaceuticals Inc., to its Board of Directors. Foamix also announced that Mr. Chaim Chizic will transition from his current position as a Director to an observer to the Board.

Meir Eini, Chairman of the Board of Foamix commented, “We are pleased to have Aaron join the Board of Directors. His extensive pharmaceutical industry experience, in particular his long tenure at Teva, will be invaluable to Foamix. As we move forward with the development of our advanced clinical programs utilizing our proprietary foam technologies, we continue to seek out seasoned industry experts who can provide insight and guidance.”

“I am excited to have the opportunity to join the Foamix board,” said Dr. Schwartz. “I believe that Foamix is positioned to become an important global player in dermatology and I look forward to working with the Company as it advances.”

Dr. Schwartz is currently chairman of the board for several life science companies, including DPharm Ltd., BioCancell Ltd., CureTech Ltd., BiolineRx and Biomas Ltd. Dr. Schwartz also serves on the board of directors of Protalix Ltd. and as a consultant to Clal Biotechnology Industries Ltd. Dr. Schwartz received a Ph.D. in organic chemistry from the Weizmann Institute, an M.Sc. in organic chemistry from the Technion and a B.Sc. in chemistry and physics from the Hebrew University of Jerusalem. He recently received a second Ph.D. from the Hebrew University of Jerusalem in the history and philosophy of science.